Last year’s Brexit vote added further uncertainty to an already precarious life sciences IP market. And, with the Unified Patent Court now thrown into confusion, the political and legislative landscape is one to navigate with caution. Against this backdrop, the 2nd (Annual) Pharma and Biotech IP Summit will once again bring together leading IP experts from across life sciences. Attendees will hear the latest IP strategies for thriving at a time when regulatory and legislative changes are significantly impacting business models.
For more information click here